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A recent  study showed that cAMP analogs lowered 
cAMP levels in rat hepatocytes (Corbin, J. D., Beebe, 
S .  J., and Blackmore, P. F. (1985) J. Biol. Chern. 260, 
8731-8735). The  present  work  demonstrates that 
cAMP analogs also lowered cAMP in a rapid, concen- 
tration-dependent manner in heart and fat cells. In 
order to  determine if the CAMP-dependent protein  ki- 
nase mediated this effect, techniques were developed 
to  assay  the  protein  kinase  activity ratio  in hepatocytes 
treated  with cAMP analogs. The  activation of protein 
kinase  and phosphorylase in hepatocytes by 8-pC14S- 
cAMP (where 8-pClI#JS- indicates 8-parachlorothio- 
phenyl-) was  concentration-dependent  and  occurred  in 
parallel to proportionate decreases in CAMP. More 
than 20% of the cAMP binding sites on the protein 
kinase  were unoccupied at concentrations of 8-pClgS- 
cAMP that produced maximal cAMP lowering. Thus, 
the possibility that 8-pCl4S-cAMP lowered cAMP  by 
displacing it from  protein  kinase  binding sites, making 
it available  for hydrolysis, seemed unlikely. In adipo- 
cytes, the lowering of cAMP by 8-pC14S-cAMP oc- 
curred  in parallel  with  increases in lipolysis and  acti- 
vation of low K,,, phosphodiesterase, suggesting that 
the phosphodiesterase was responsible for  the cAMP 
lowering. Further evidence for  this  assertion  was  the 
finding that  in hepatocytes preloaded with low  concen- 
trations of  8-pCL$S-cAMP, glucagon lowered 8-pClI#JS- 
cAMP by about 50%, an amount similar to the cAMP 
lowering observed with 8-pClI#JS-cAMP treatment.  The 
results  were consistent with a CAMP-dependent pro- 
tein kinase-catalyzed activation of a phosphodiesterase 
and suggested that 8-pCl4S-CAMP-mediated hydroly- 
sis of cAMP mimicked a physiologically significant 
response. The  observation of this phenomenon in  sev- 
eral tissues further suggested that  it may be a general 
mechanism for  dampening  and  terminating  the  hor- 
monal signal  through  accelerated  egradation of 
CAMP. 
Chronic exposure of certain  tissues to hormones that ele- 
vate cAMP produces a state of “refractoriness” to further 
hormonal  stimulation.  Dampening mechanisms such as down- 
regulation of hormone receptors and/or uncoupling of the 
receptor-adenylate cyclase complex have been described (1- 
4) and may represent “long-loop” feedback systems. There 
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may also be present “short-loop’’ feedback systems in tissues, 
which cause a rapid dampening of cAMP levels. It has been 
reported that P-adrenergic agonists rapidly increase the activ- 
ity of  low K,,, phosphodiesterases in liver (5-6) and  fat (7-lo), 
but the relative importance of phosphodiesterase activation 
in modulating cAMP levels under these circumstances has 
been difficult to assess since cAMP levels are  determined by 
the composite of adenylate cyclase and phosphodiesterase 
activities. Cyclic AMP analogs offer the  attraction of bypass- 
ing adenylate cyclase and activating the CAMP-dependent 
protein  kinase directly (11). Several studies have shown that 
cAMP analogs activate the low K ,  phosphodiesterase (5-6, 
IO), thus predicting that they would lower cAMP levels in 
intact cells, although one early experiment showed that  the 
analog N6,02’-dibutyryl-cAMP elevated cAMP levels in  adi- 
pocytes (12). More recent work with cAMP analogs having 
high affinity for protein kinase and relatively low affinity for 
phosphodiesterase has shown that cAMP analogs lower en- 
dogenous cAMP in hepatocytes (13). Preliminary evidence 
suggests that CAMP-dependent protein  kinase mediates this 
effect, but  the mechanism and  its physiological significance 
remain unclear. The objectives of the present  study were to 
examine the mechanism of rapid cAMP lowering in hepato- 
cytes and look for occurrence of this phenomenon in  other 
cell types. Using heart, liver, and  fat cells, it is shown that 
CAMP-dependent protein kinase-mediated lowering of cAMP 
may be a general mechanism for regulating cAMP levels and 
may occur through phosphodiesterase activation. It is also 
suggested that  this phenomenon may represent an example 
of a second messenger regulating its own concentration. 
MATERIALS AND METHODS 
Preparation and Incubation of Hepatocytes-Hepatocytes  were  iso- 
lated from male Sprague-Dawley rats (200-250 g body weight) by 
collagenase perfusion as previously described (14). Cyclic AMP ana- 
logs  were added to continually gassed  cell suspensions (50 mg cells/ 
ml) incubated at 37 ‘C, and aliquots were  removed for measurement 
of phosphorylase, CAMP-dependent protein kinase, and CAMP. 50- 
and 5OO-pl aliquots of each cell suspension were  removed  for subse- 
quent assay of CAMP-dependent protein kinase and phosphorylase, 
respectively. Cyclic AMP was assayed in cell pellets obtained by 
centrifuging (500 X g) 4 ml of cell suspension and decanting the 
supernatant.  Both aliquots and  the cell pellet were immediately frozen 
in liquid nitrogen and stored at -70 “C. 
Protein Kinase Assay-The protein kinase activity ratio was deter- 
mined by a modification of the filter paper assay of Roskoski (15), 
using a synthetic heptapeptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) as 
substrate. Preliminary studies were undertaken to assure that the 
activity ratio could be accurately measured in hepatocyte incubations 
containing cAMP analogs. The use of larger than normal volumes of 
homogenizing buffer diluted the cAMP analogs and circumvented the 
problem of additional activation of the enzyme after homogenization. 
4 ml of homogenizing buffer containing 10 mM KH,PO,, 150 mM 
KCl, 10 mM EDTA, 0.5 mM 3-isobutyl-l-methylxanthine, and bovine 
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serum albumin (BSA,' 0.5 mg/ml) were added to the cell pellet, and 
the suspension was homogenized for 15 s using an Ultra-Turrax 
TissuemizerO. Homogenates (25 pl) were immediately assayed for 
protein kinase activity in the presence and absence of 5 p~ cAMP 
(16). The reaction was terminated  after 20 min of incubation at 30 "C. 
The reaction was linear  in the presence and absence of cAMP for at 
least 30 min. 
Phosphorylase Assay-Frozen aliquots of the cell suspensions were 
thawed for 10 min and homogenized for 10 s in 1 ml of buffer 
containing 150 mM @glycerophosphate, 30 mM EDTA, 150 mM NaF, 
600 mM sucrose, and 6.5 mg/ml cysteine. Homogenates were assayed 
for phosphorylase activity as previously described (14). 
Purification and Assay of CAMP-Crude extracts were prepared by 
homogenizing cell pellets in 1 ml of cold buffer containing 25 mM 
NH,HC03, 1 mM 3-isobutyl-l-methylxanthine, and 20  mM EDTA. 
The homogenate was  boiled for 6 min and centrifuged for 7 min in a 
Beckman Microfuge B. Tritium-labeled cAMP (-20,000 dpm) was 
mixed with 0.5 ml of the extract and chilled before Sephadex G-25 
(superfine) chromatography (0.9 X 14 cm) at 4 "C. 1-ml fractions 
were collected, and 50-pl aliquots of the fractions were counted to 
locate the cAMP peak and calculate recovery in these fractions. Cyclic 
AMP was assayed in the appropriate fractions (11-15, VJV, = 1.62) 
using Type 1 CAMP-dependent protein kinase purified from rabbit 
muscle (17). Incubation of the assay was at 4 "C for 16 h, as previously 
described (13). 
Few studies have been reported in which cAMP levels have been 
measured in tissues treated with cAMP analogs (12-13). It is impor- 
tant  to purify cAMP analogs prior to use, since any cAMP contami- 
nation of the original preparation will copurify with endogenous 
cAMP and inflate the estimated concentration. Other  contaminating 
cyclic nucleotides may also copurify and cross-react in the cAMP 
assay. Preliminary studies in this lab (data not reported) with car- 
diomyocytes revealed that cyclic nucleotide contamination in com- 
mercial analog preparations  can be substantial and interfere meas- 
urably in cAMP assays. The 8-pClqhS-CAMP used for cell incubations 
was first chromatographed on  a 0.9 X 57-cm Sephadex G-25 superfine 
column as previously described (12). The peak fractions of the elution 
profile (V,/V, = 2.36-2.81) were combined and standardized on the 
basis of absorbance at 281 nm. 
Assay of 8-pC1qhS-CAMP-In some experiments, hepatocytes were 
incubated with 0.015 p~ 8-pClqhS-CAMP in the presence and absence 
of glucagon (5  X lo-' M),  and 8-pClqhS-CAMP  was sayed. Incubation 
of hepatocytes with this concentration of 8-pC1&3-cAMP did not 
detectably activate protein kinase or phosphorylase. Crude extracts 
were prepared and chromatographed as described for purification of 
CAMP, except that fractions containing 8-pClqS-cAMP were retained 
for assay. Sephadex G-25 chromatography at 4 "C separated cAMP 
(VJV, = 1.62) from 8-pClqhS-CAMP (VJV, = 2.78) completely (13). 
Since labeled 8-pCl@S-cAMP was unavailable, all fractions (20-30) 
expected to contain 8-pClqScAMP ( Ve/Vt = 2.36-2.81)  were pooled. 
The pooled fractions from each incubation were lyophilized and 
resuspended in 25 mM NH4HC03. 60-pl aliquots were assayed using 
Type 1 CAMP-dependent protein kinase as described for the assay of 
CAMP. Purified 8-pClqhS-CAMP dissolved in the elution buffer was 
used as the standard. The K,, of Type 1 CAMP-dependent protein 
kinase for 8-pC14S-cAMP was about half that for CAMP. 
Assay of CAMP Binding Sites-In some experiments, the protein 
kinase activity ratio and  the number of free and  total cAMP binding 
sites on protein kinase were assayed in the same hepatocyte incuba- 
tion. Free cAMP binding sites  on the regulatory subunit were esti- 
mated by taking advantage of the difference between the rates of 
cAMP binding and dissociation (fast binding, slow dissociation). The 
procedure was initiated by adding 100 p1 of sample to 50 p1 of reaction 
mixture containing 50 mM KH2P04 (pH 6.8), 1 mM EDTA, 0.5  mg/ 
ml Type 11-A histone mixture (Sigma), 2 M NaC1,  0.1 mM adenosine, 
and 1.8 p~ [3H]cAMP. After 5 min at  0 "C, 1 ml of cold 10 mM 
KH2P04  (pH 6.8) containing 1 mM EDTA was added, and  the mixture 
filtered and washed using Millipore filters (18). The  total [3H]cAMP 
binding sites were measured using the same procedure except that 
incubation was at 30 "C for 45 min. Exchange of prebound cAMP 
was complete under these conditions (18). The proportion of free 
sites was expressed as the ratio of cAMP bound at 0 and 30 "C. 
In other experiments, free and total cAMP binding sites were 
The abbreviations used are: BSA, bovine serum albumin; 8- 
pCl$S-, 8-parachlorothiophenyl-; V,/V,, elution volume/total column 
volume; TES, N-tris[hydroxylmethyl]methyl-2-aminoethanesulf0nic 
acid. 
assayed in incubations with Type I CAMP-dependent protein kinase 
partially purified through the DEAE-cellulose step (17). The activity 
ratio was varied by the addition of various concentrations (31-1000 
nM) of 8-pClqhS-CAMP to a total volume of 95 pl reaction mixture 
containing 6 pmol of holoenzyme, 20  mM Tris-HC1 (pH 7.4),  0.05 mM 
3-isobutyl-l-methylxanthine, 65 pM heptapeptide (Kemptide), 10 mM 
Mg(CH&00)2, 0.1 m M  13*P]ATP (-100 cpm/pmol), and 0.39 p~ 
[3H]cAMP in the presence and absence of 2 p~ cold CAMP. After 
incubation at 4 "C, 50-pl aliquots were spotted on phosphocellulose 
papers for determination of 32P incorporation. To  the 45  p1  of reaction 
mixture remaining, 1 ml of cold 10 mM KH2P04 containing 1 mM 
EDTA was added, and this sample was filtered immediately by 
Millipore filtration as previously described (18). 
Preparation and Incubation of Adipocytes-Adipocytes were iso- 
lated from epididymal fat pads of 200-250 g male Sprague-Dawley 
rats by collagenase treatment according to Rodbell (19). The cells 
were washed and resuspended (10 mg cells/ml suspension) in Krebs- 
Ringer bicarbonate buffer containing 1 mM CaClz and 2% BSA. 
Duplicate incubations were carried out in closed vials gassed with 
95% 0 2  and  5% CO2 in the presence or absence of various concentra- 
tions of 8-pCl@S-cAMP. At the end of a 15-min incubation, the cells 
were washed twice with 0.25 M sucrose in 10 mM TES, and one 
replicate of each incubation was immediately homogenized with 1 ml 
of cold buffer containing 25 mM NHdHCO3, 1 mM 3-isobutyl-meth- 
ylxanthine, and 20 mM EDTA. The homogenate was  boiled for 6 min 
and centrifuged for 7 min in  a Beckman Microfuge B. The aqueous 
phase was  recovered and chromatographed at 4 "C on Sephadex G- 
25, and cAMP was assayed in the appropriate fractions as described 
for hepatocytes. The other replicate of each incubation was retained 
for assay of phosphodiesterase. Glycerol release was determined in 
similar incubations according to  the method described by Beebe et al. 
(20). 
Assay of Low K,,, Phosphodiesterase-Crude microsomal fractions 
(P-2) were prepared from each adipocyte incubation, and phospho- 
diesterase activity was measured according to  the method described 
by Kono (21). The assay procedure involved measurement of adeno- 
sine formation from tritiated cAMP hydrolysis by phosphodiesterase 
and snake venom nucleotidase. The reaction was initiated by adding 
50  pl of the crude enzyme to 200 pl of reaction mixture containing 50 
mM TES (pH 7.5), 0.125 p~ unlabeled CAMP, 1 pCi [3H]cAMP 
(specific activity 31 Ci/mmol), and 5 mM MgSO,. The reaction was 
stopped after  a 5-min incubation at  30 'C by adding 250 pl of an 
equimolar mixture of cAMP and AMP (1 mM each) and immediately 
boiling for 3 min. After the tubes cooled, 50 pl of 5 mg/ml snake 
venom in 0.1 M Tris  (pH 8) was added to each tube and incubated 
for 30 min at  37 "C. This reaction was terminated by a 50-pl addition 
of 5 mM adenosine in 200 mM EDTA. Tritiated adenosine was 
separated from 13H]cAMP by QAE-Sephadex and counted. Protein 
in each original enzyme preparation was determined by the method 
of Bradford (22), and phosphodiesterase activity was expressed as 
pmol of cAMP hydrolyzed/min/mg of protein. 
Preparation and Incubation of Cardiomyocytes-Cardiomyocytes 
were isolated by collagenase perfusion of rat hearts as described 
previously (23-24) with slight modification. Hearts were removed 
quickly from anesthetized rats (250-300 g) and perfused by the 
Langendorff procedure. The initial perfusion was for 10 min at 60 
mm mercury with Krebs-Henseleit bicarbonate buffer (37 "C, pH 7.4) 
containing 1.25 mM Ca2+ and 10 mM glucose (25). The perfusion was 
continued for 5 additional min (8 ml/min) with no Ca" in  the buffer. 
The final perfusate was changed to include 12.5 p~ Caz+, 0.1% 
collagenase, and 0.1%  BSA, and perfusion continued for 14 min (8 
ml/min). The ventricles were excised and incubated for 10 min on  a 
shaker bath  at 37 "C in 5 ml of Krebs-Henseleit bicarbonate buffer 
containing 12.5 p~ Ca2+, 0.1% collagenase, and 2% BSA. The initial 
supernatant was discarded and 5 ml of fresh buffer  added. Isolated 
cells were harvested by repeated (three times) 5-min incubations in 
the collagenase buffer, followed by pouring the suspended cells 
through nylon mesh after each incubation. Cells  were centrifuged at 
low speed after two washes in Krebs-Henseleit buffer containing 12.5 
p~ Ca2+ and 2% BSA. The cells were subsequently incubated on a 
shaker bath for 10 min at 37 "C in Krebs-Henseleit buffer containing 
12.5 p~ Ca2+ and 2% BSA. The cells were then allowed to settle twice 
under gravity; the first  time for 10 min at room temperature and  the 
second for 5 min at room temperature in a  final Krebs buffer con- 
taining 10 mM glucose, 1.8 mM Ca2+, and 0.01% BSA. Cells were 
resuspended in this buffer at a concentration of 180,000 cells/ml and 
preincubated for 5 min at 37 "C before addition of 8-pCl$S-cAMP. 
Following a 15-min incubation, cells were centrifuged at 500 X g for 
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5 min at 0 “C. Incubation medium  was decanted, and the cell pellet 
was  immediately  frozen  in  liquid  nitrogen and stored at -70 “C. Cyclic 
AMP  was  assayed in cell extracts after purification as described  for 
hepatocytes.  Phosphorylase  activity was  measured  in the cell pellets 
as  previously  described (14). 
Methods of Analysis and Response Variable Characterizations- 
Response variables from experiments in the present study were 
characterized  using relationship functions appropriate to  the shape 
of the response surface. Responses such as the CAMP-dependent 
protein  kinase  activity ratio and phosphorylase  activation in relation 
to concentration of 8-pCl@S-cAMP were adequately  characterized by 
the exponential given as 
y = (Y - p(2)-”@ (1) 
where y = response  variable (protein kinase or phosphorylase activ- 
ity), x = concentration of 8-pClqS-cAMP (pM) ,  a = asymptotic value 
of y at infinite x ,  = CY - y at x = 0, and p = x at (a/2)  + y intercept. 
The CAMP-lowering  response  in relation to increasing concentrations 
of  8-pC16S-cAMP or in relation to time was characterized by 
y = 6 + x(2)-”/’ (2) 
where y = response  variable (CAMP concentration), x = concentration 
of 8-pClqScAMP or time, 6 = concentration of  cAMP at infinite x ,  
X = y intercept - 6, and T = x at (1/2 y intercept) + 6. 
Parameter estimates, along with an estimate of their standard 
errors, were obtained  for Equations 1 and 2 using an iterative nonlin- 
ear least  squares routine in  SAS (Statistical Analysis  System,  Cary, 
NC). The parameter p, in the case of CAMP-dependent protein  kinase 
activity ratio or  phosphorylase activation, is analogous to the more 
familiar K, in the sense that  it represents the value of x (8-pC16S- 
cAMP concentration) producing a half-maximal  response. In the case 
of the CAMP-lowering response, the parameter 7 also represents the 
value of x (S-pClqS-cAMP concentration or time) where the half- 
maximal  response  is  seen. The parameter estimates for p and 7 thus 
provide a convenient  basis for comparing the concentration or time 
dependence  of the various  responses  within and across  tissues. 
The results from experiments where  8-pC1&3-cAMP  was  measured 
in hepatocytes treated with  various  CAMP-dependent protein kinase 
activators were  analyzed  by a one-way  analysis of variance (26). The 
criterion employed  for assessing treatment differences was  based  on 
a level of protection  against  Type I errors of 1% (a = 0.01). 
RESULTS 
Protein Kinase Activity Ratio Validation-Replicate ali- 
quots of hepatocytes were incubated  with  various  concentra- 
tions of 8-pCl@S-cAMP, and the cells  were  homogenized in 
different volumes (1, 2, 4, 10, and 50 ml) of buffer. Protein 
kinase  activity  ratios were assayed  with  the  intent of choosing 
a homogenization volume  which prevented  subsequent  protein 
kinase activation by analog carryover when the cells were 
broken.  At  higher  8-pCl$S-cAMP  concentrations (>0.1 p ~ ) ,  
the  assayed  CAMP-dependent  protein  kinase  activity  ratios 
differed among homogenization volumes (data not shown). 
This would be  expected if extracellular  8-pClqS-cAMP  in  the 
original  incubation  was  not  sufficiently  diluted  in  the homog- 
enization volume. A homogenization volume of 4 ml was 
chosen  since  the  activity  ratios  using 4, 10,  and  50  ml were 
consistent regardless of 8-pC14S-cAMP concentration, a re- 
sult  not  seen  with 1 or 2 ml (data  not  shown).  Further vidence 
that 4 ml of homogenization  buffer  provided  the  conditions 
for  accurate  in  situ  activity  ratio  estimates was obtained by 
examining  the  relationship  between  phosphorylase  activation 
and  CAMP-dependent  protein  kinase  activity  ratio  in  hepa- 
tocytes  incubated  with  several  concentrations of glucagon and 
8-pClqS-cAMP.  The  original  observations  and  fitted  curves 
are  presented  in Fig. 1. Assuming  that glucagon acts  entirely 
by cAMP elevation, a given increment of protein kinase 
activation by glucagon or  8-pClqS-cAMP  should  produce  the 
same  increment of phosphorylase  activation. A formal  test of 
the  similarity  between  response  curves was  provided by com- 
paring  maximal  phosphorylase  activation (CY) and the  CAMP- 
dependent  protein  kinase  activity  ratio a t  half-maximal  phos- 
PROTEIN KINASE ACTIVITY RATIO - (;:E43 
FIG. 1. The relationship between protein kinase activity 
ratio and  phosphorylase activity in hepatocytes treated with 
8-pCl$S-cAMP (0) or  glucagon (0). The  original  observations are 
the mean of four  replicates  within  each of four  experiments, and the 
fitted curves  were obtained by least  squares.  Hepatocytes were incu- 
bated  with  various concentrations of  8-pC16S-cAMP or glucagon  for 
5 min.  Aliquots  were retained  and  assayed  for  protein  kinase  activity 
ratio and phosphorylase  activity  as  described  under “Materials and 
Methods.” G-I-P, glucose 1-phosphate. 
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FIG. 2. Effect of 8-pClqjS-CAMP concentration on protein 
kinase activity ratio (O), phosphorylase activity (A), and en- 
dogenous cAMP (0) in hepatocytes. The  original  observations are 
the mean of duplicate determinations within  each of five experiments, 
and the fitted curves were obtained by least squares. Hepatocytes 
were incubated for 5 min with the indicated concentrations of 8- 
pCl6S-CAMP. Extracts were prepared and processed as described 
under “Materials and Methods.” G-I-P, glucose 1-phosphate. 
phorylase  activation (p) from  the  fitted glucagon (CY = 12.71 
f 0.30, p = 0.242 f 0.025) and  8-pCldS-cAMP ( a !  = 12.98 & 
1.01, g = 0.311 f 0.083) curves. No evidence was seen to 
suggest that  the  response  curves were different. 
It should be noted  that  this  technique of using large ho- 
mogenization  volumes is ineffective in  most cell types,  since 
much  greater  concentrations of analog (500-2000 times 
greater)  are  required  to  produce  cellular responses. Thus,  the 
carryover of analog  when  the cells are broken artifactually 
elevates  the  CAMP-dependent  protein  kinase  activity  ratios. 
Effect of CAMP Analogs on  Hepatocyte CAMP-The cAMP 
analog,  8-pCl@S-cAMP,  activated  hepatocyte  protein  kinase, 
phosphorylase, and lowered cAMP in a concentration-de- 
pendent manner. The concentrations required to produce 
changes  in  each  response were similar among all responses 
(Fig. 2). The concentrations of 8-pC14S-cAMP required to 
produce  half-maximal  protein  kinase  activation (g = 0.071 & 
0.010 pM), half-maximal  phosphorylase  activation (p = 0.031 
& 0.006 pM), and  half-maximal  cAMP lowering (7 = 0.036 f 
0.006 gM) were similar among the measures, as was the 
concentration of 8-pC1dS-CAMP (0.125 pM), producing  nearly 
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maximal responses of all measures. 
Hepatocyte CAMP Binding Studies-CAMP analogs, includ- 
ing 8-pCl$S-cAMP, are known to bind to  the R-subunit of 
CAMP-dependent protein kinase with high affinity (27-28). 
It was important to rule out the possibility that 8-pCldS- 
cAMP was  lowering endogenous cAMP by displacing bound 
cAMP from CAMP-dependent protein kinase, thus making it 
available for hydrolysis by phosphodiesterase. It can be seen 
in Fig. 2 that CAMP-dependent protein kinase activation 
occurred in parallel to  the decline in CAMP, so evidence of 
free binding sites at concentrations of 8-pCl#S-cAMP that 
maximally lowered cAMP would argue against a competitive 
mechanism for the lowering. Reference to Fig. 3 indicates 
that  as  the activity ratio increased from 0.2 to 0.7 (maximal 
activation = I), the percentage of free cAMP binding sites 
decreased proportionately. Concentrations of 8-pCldS-cAMP 
that produced an activity ratio of 0.7 also lowered cAMP 
maximally. These results suggested that cAMP binding sites 
were not  saturated at this  concentration of analog, and  in fact 
free cAMP binding sites were detected. Similar studies in a 
cell-free system using physiological concentrations of partially 
purified CAMP-dependent protein kinase indicated the pres- 
ence of free cAMP binding sites at activity ratios of 0.90 or 
lower  (Fig. 4). Using both  intact cells and  the partially purified 
enzyme, free cAMP binding sites declined with increased 
concentrations of 8-pCl@S-cAMP, but maximal cAMP low- 
ering occurred at activity ratios where excess cAMP binding 
sites were still available. 
Assay of S-pCl$S-cAMP in Hepatocytes-Incubation of he- 
patocytes with 0.015 /IM 8-pCl@S-cAMP resulted in no de- 
tectable activation of CAMP-dependent protein kinase, but 
the analog could readily be assayed in extracts of the hepa- 
tocytes. Addition of glucagon ( 5  nM), forskolin (20 pM),  or 
N6,02’-dibutyryl-cAMP (20 p ~ )  resulted in lowering of 8- 
pCl$S-CAMP in hepatocytes preloaded with the analog (Table 
I). The N6,02’-dibutyryl-cAMP lowered 8-pCldS-cAMP sig- 
nificantly but was less effective than glucagon or forskolin. 
Glucagon produced the most substantial lowering of 8-pCldS- 
cAMP (-50%), and  the percentage decrease was quite similar 
to  the percentage decrease in endogenous cAMP seen when 
optimal concentrations of 8-pC14S-cAMP (0.25 pM) were used 
to activate CAMP-dependent protein kinase. Addition of glu- 
cagon or forskolin to hepatocytes at the indicated concentra- 
,”-- 
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FIG. 3. The relationship between cAMP binding site occu- 
pancy (0) and protein kinase activity ratio (0) in hepatocytes 
treated with various concentrations of 8-pC1bS-CAMP. The 
original observations are the mean of duplicate determinations within 
each of three experiments. Hepatocytes were incubated for 5 min 
with various concentrations of 8-pCI4S-cAMP. Cells were homoge- 
nized, and free and total cAMP binding sites were determined as 
described  under “Materials and Methods.” 
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FIG. 4. The relationship between protein kinase activity 
ratio and free cAMP binding sites on Type 1 CAMP-dependent 
protein kinase incubated with various concentrations of 8- 
pC1bS-CAMP. The original observations are the mean of duplicate 
determinations within each of three experiments. The enzyme was 
partially purified from rabbit skeletal muscle through the DEAE- 
cellulose step (33), and 2.8 pmol of the holoenzyme was used for each 
binding determination. 
TABLE I 
Assay of 8-pCLpS-cAMP in hepatocytes preloaded with the analog 
and treated with various agents to activate CAMP-dependent protein 
k i m e  
Treatment 8-pCl&- Protein kinase CAMP” activitv ratio 
pmol/g tissue 
Control 36.47 0.24 
5 nM glucagon 18.36 0.81 
20 NM forskolin 21.40 0.80 
S.E.’ 0.63 0.04 
20 pM dibutyUl-cAMP 30.20 b -
’Hepatocytes were preincubated with 0.015 p~ 8-pCl4S-cAMP 
for 5 min and treated in  the indicated manner for 5 additional min. 
Aliquots were removed for determination of the CAMP-dependent 
protein kinase activity ratio, and the concentration of 8-pC14S-cAMP 
in the cell pellet was determined. The means and their corresponding 
standard  errors  were estimated from  four experiments. 
Accurate estimates of the CAMP-dependent protein kinase activ- 
ity ratio were not obtained in  this incubation. 
e Standard error  of the mean  from analysis of variance. 
tions resulted in nearly maximal CAMP-dependent protein 
kinase activation (Table  I). 
It was presumed that 20 p~ N6,02‘-dibutyryl-cAMP also 
activated protein kinase substantially. Accurate estimates of 
CAMP-dependent protein kinase activity could not be ob- 
tained with 20 p~ N6,02’-dibutyryl-cAMP due to analog 
carryover, but previous studies have shown that  this concen- 
tration of the analog activated phosphorylase.’ 
Effect of cAMP Analogs on Adipocytes-Glycerol release, 
low K,,, phosphodiesterase activation, and cAMP lowering 
occurred in response to increasing concentrations of 8-pCldS- 
cAMP in adipocytes (Fig. 5). The concentration of analog 
required to produce half-maximal glycerol release (171 k 14 
p ~ )  and phosphodiesterase activation (140 f 11 p ~ )  were 
similar, but were somewhat higher than the concentration 
(106 f 9 p ~ )  required for half-maximal cAMP lowering. 
Higher concentrations of 8-pCldS-CAMP were required to 
elicit all responses in fat cells than in hepatocytes. This 
finding was consistent with previous studies using cAMP 
analogs in different tissues (11) and may  be  due to differences 
in cell permeability. Nevertheless, the percentage decrease in 
endogenous cAMP produced by optimal 8-pCldS-cAMP con- 
centrations (-60%) was similar to  the cAMP decrease seen 
P. F. Blackmore, unpublished observations. 
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FIG. 5. Effect  of 8-pC14S-cAMP concentration on glycerol 
release (0), low K,,, phosphodiesterase (PDE) activation (O), 
and endogenous cAMP (0) in adipocytes. The original  observa- 
tions are the mean of duplicate determinations within each of five 
experiments. Adipocytes were incubated for 15 min  with the indicated 
concentrations of 8-pCl+S-cAMP. Extracts were prepared and proc- 
essed as described  under “Materials and Methods.” Estimates of the 
concentration of analog required to produce half-maximal glycerol 
release  and  phosphodiesterase  activation were obtained from fitted 
logistic  ogives as described  previously (51). 
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FIG. 6. Time course of cAMP in control adipocytes (0) and 
adipocytes treated with 200 p t ~  8-pC14S-cAMP (0). The origi- 
nal observations are the mean of duplicate determinations within 
each of four  experiments, and the fitted lines were obtained by least 
squares. Extracts were prepared and processed as described under 
“Materials and Methods.” 
in  hepatocytes (-50%). Incubation of adipocytes  with 200 pM 
8-pCl4S-CAMP  produced a rapid 49% decline (7 = 2.23 +. 0.67 
min,  half-time  for  maximal lowering) in  CAMP,  whereas  basal 
cAMP  in  control cells  decreased  slightly during  the  30-min 
incubation (Fig. 6). A previous report demonstrated rapid 
cAMP lowering in hepatocytes (13) and  reanalysis of those 
data  produced  an  estimate  for 7 (half-time for maximal  cAMP 
lowering) of 0.55 & 0.16 min. Inasmuch  as  the process ap- 
peared to  be  somewhat slower in  fat cells than  hepatocytes, 
the  hypothesis  that  the  half-times were different  in  the two 
tissues was rejected. 
Effect of cAMP Analogs on Cardiomyocytes-The concen- 
tration of 8-pC19S-cAMP  required to  activate  phosphorylase 
in cardiomyocytes (Fig. 7) was somewhat less than  the  con- 
centration  required  to lower cAMP  in adipocytes, but was still 
substantially higher than  in  hepatocytes.  Incubation of car- 
diomyocytes with 70 p~ 8-pC14S-cAMP achieved approxi- 
mately 80% maximal  activation of phosphorylase; a  concen- 
tration of  37.2 -C 4.2 p~ ( p )  produced half-maximal  activation. 
Under  the  conditions used, it was not possible to  determine 
accurately the CAMP-dependent protein kinase activity ra- 
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FIG. 7. The relationship between phosphorylase activity (0) 
and endogenous cAMP (0) in cardiomyocytes treated with 
various concentrations of 8-pC14S-cAMP. The original  obser- 
vations are the mean of four  replicates  within each of four experi- 
ments, and the fitted curves were obtained by least squares. The 
cardiomyocytes were incubated for 15 min with various concentra- 
tions of 8-pClbS-cAMP. Extracts were prepared and processed as 
described under “Materials and Methods.” G-I-P, glucose l-phos- 
phate. 
tios,  since carryover of the  analog when the cells were broken 
produced additional enzyme activation.  Basal  cAMP was low- 
ered in the same 8-pC16S-cAMP concentration range that 
activated phosphorylase, but the concentration producing 
half-maximal lowering of CAMP (T = 13.99 f 5.46 p M )  was 
less. Even so, reference to Fig. 7 illustrates  the good correla- 
tion between phosphorylase  activation  and  cAMP lowering. 
The  percentage decline (-60%) in basal cAMP  in cardiomy- 
ocytes treated  with 70 KM 8-pC16S-cAMP was similar to  the 
cAMP decline seen in adipocytes (-60%) and hepatocytes 
(-50%) and  the  8-pClqScAMP decline (-50%) seen in glu- 
cagon-treated hepatocytes. 
DISCUSSION 
Previous  studies have  shown that  interactions  among  var- 
ious hormones modify cellular cAMP  concentrations  in some 
cell types. Some  hormones  are  thought  to  exert  their effects 
by decreasing cAMP levels. The ability of insulin  to decrease 
cellular cAMP levels in glucagon-stimulated hepatocytes (29- 
33) and epinephrine-stimulated adipocytes (34-35) is well 
documented. Buxton and Brunton (36) have described in 
cardiomyocytes a decreased P-agonist-induced cAMP accu- 
mulation by an  a,-agonist-mediated  activation of phosphodi- 
esterase.  Dumont et al. (37) have shown that  norepinephrine 
(a2) decreases thyroid-stimulating  hormone-stimulated  ade- 
nylate cyclase activity in thyroid slices, and cy2 agents are 
known to  cause decreases in  cAMP  in several other  tissues by 
acting  through  the Ni (inhibitory guanyl nucleotide-binding 
regulatory protein of adenylate cyclase) pathway (38). It  has 
also been  reported  that  increased cytosolic calcium activates 
a  calmodulin-sensitive phosphodiesterase  in some tissues (39). 
These heterologous types of cAMP  control may be  important 
in modifying cellular  responses to hormones. This  laboratory 
has  recently described a homologous type of cAMP  control  in 
which  CAMP-dependent protein  kinase  activation lowers he- 
patocyte  CAMP. Additional evidence that  cAMP may act  to 
regulate its own concentration  can be found  in  reports which 
have  shown  that  hormones which elevate cAMP activate a 
hormone-sensitive  phosphodiesterase  in several cell types (5- 
8,10,40),  and  it  has  been  reported  that a low K,,, phosphodi- 
esterase  can  be  phosphorylated by protein  kinase (41). Other 
examples of homologous regulation of second  messenger con- 
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centrations  can be found in  reports which  show that elevation 
of cytoplasmic Ca2' results in activation of mechanisms which 
quickly lower cytoplasmic Ca2+ (42), and elevation of cyto- 
plasmic diacylglycerol has also been reported to cause a  sub- 
sequent decline in cytoplasmic levels of this second messenger 
(43). 
The present  results  support the suggestion by this labora- 
tory that CAMP-dependent protein kinase mediates the low- 
ering of CAMP. Likely targets for CAMP-dependent protein 
kinase would be the adenylate cyclase complex or low K ,  
phosphodiesterases, the former decreasing cellular cAMP by 
slowing synthesis and  the  latter by enhancing  cAMP degra- 
dation. The present observation that glucagon enhances 8- 
pC1dS-CAMP breakdown in hepatocytes suggests that a cel- 
lular phosphodiesterase(s) is being activated by protein ki- 
nase. The finding that 8-pCldS-cAMP activated a low K,,, 
phosphodiesterase in the same  concentration range that pro- 
duced cAMP lowering in adipocytes further suggests that 
cAMP is being lowered by phosphodiesterase activation. This 
does not rule out  the possibility that cAMP analogs may have 
an additional effect to lower cAMP by modifying adenylate 
cyclase activity, but it should be  pointed out  that glucagon- 
mediated lowering of 8-pC14S-cAMP was nearly the same, on 
a percentage basis, as analog-mediated cAMP lowering. I t  will 
be of interest to confirm that phosphodiesterases are respon- 
sible for cAMP lowering under these  circumstances and iden- 
tify which form of phosphodiesterase is the  target enzyme. 
The finding that  the lowering of cAMP  in adipocytes is  well- 
correlated with activation of the low K ,  form of phosphodi- 
esterase is strongly suggestive that  this enzyme is the one 
acted on by protein kinase. Another possibility considered is 
that cytoplasmic 8-pC1dS-CAMP displaces cAMP from its 
binding sites on CAMP-dependent protein kinase, thus  stim- 
ulating phosphodiesterase activity by increasing substrate 
availability. The results obtained in binding studies with 
intact hepatocytes and with partially purified holoenzyme 
argue against  such  a mechanism. Free binding sites  are de- 
tected in both systems with 8-pCl@S-cAMP concentrations 
and CAMP-dependent protein kinase activity ratios which 
produced maximal cAMP lowering. These findings suggest 
that additional  8-pCldS-cAMP would have to fill remaining 
binding sites before significant cAMP displacement would 
occur. Although in the basal state the proportion of total 
endogenous cAMP bound to CAMP-dependent protein kinase 
compared to unbound cAMP is large, previous studies  have 
shown that addition of  low concentrations of cAMP analogs 
to the holoenzyme actually stimulates cAMP binding (44). 
The results  presented here argue in favor of a CAMP-depend- 
ent protein  kinase-mediated mechanism rather  than  an  arti- 
factual lowering through competition and displacement from 
binding  sites. 
This laboratory has recently suggested that lowering of 
hepatocyte cAMP by protein kinase activation may be a form 
of negative feedback. The earlier findings and the results 
presented here provide evidence that CAMP-dependent pro- 
tein kinase regulates cellular cAMP levels and may represent 
a  short-loop feedback system for CAMP. Although it seems 
plausible that  this feedback system serves to dampen cAMP 
levels, other functions are possible. Recent  studies have shown 
that @-agonists increase the fractional  turnover rate for cAMP 
(45), and it has been suggested that cAMP  turnover may be 
a central component in  stimulus-response coupling (46). Ob- 
viously, the coupled stimulation of adenylate cyclase and 
phosphodiesterase activities would increase the turnover rate 
of CAMP. Long-loop feedback systems involving mechanisms 
which produce desensitization and/or down-regulation of hor- 
mone receptors have also been described (1-4). The action of 
these  systems  results  in diminished cAMP accumulation after 
chronic exposure to hormones, and refractoriness to  further 
hormonal stimulation. It has been assumed generally that  the 
long-loop feedback systems act through the receptor-adenyl- 
ate cyclase, although a role for phosphodiesterase has not 
been ruled out. Recent work has demonstrated  a 2-fold induc- 
tion of the low K ,  phosphodiesterase in  cultured cells con- 
stantly exposed to isoproterenol or cAMP analogs (47). Per- 
haps part of the refractoriness of these cells to hormonal 
stimulation can be explained by CAMP-dependent protein 
kinase-mediated activation of the additional  phosphodiester- 
ase that is present. It seems likely that the interaction of 
these various mechanisms is important in determining the 
hormone sensitivity of particular cells at  any given time. 
Previous studies have demonstrated the existence of low 
K ,  phosphodiesterases in cardiac tissue (48-50), but  to our 
knowledge it has not been shown that these forms of the 
enzyme are activated by either insulin or hormones which 
elevate CAMP. Comparable forms of the enzyme from liver 
(5-6) and adipose tissue  (7-8,lO) are hormone-sensitive. The 
observation that cAMP analogs lower endogenous cAMP in 
cardiomyocytes suggests the presence of a low K, hormone- 
sensitive phosphodiesterase in  this tissue, and  this technique 
may provide a  convenient method for detecting the CAMP- 
activated enzyme in other tissues. 
All tissues examined (hepatocytes, cardiomyocytes, and 
adipocytes) to  date have shown an 8-pC14S-cAMP-induced 
lowering of CAMP, which is analog concentration-dependent. 
The analog-induced cAMP lowering in the examined cell 
types is a  consistent response in the sense that  the proportion 
of  CAMP decline is similar among all cell types. These findings 
suggest that  the 8-pCldS-CAMP induced lowering of cAMP 
mimicks a physiologically significant response and may be 
mediated by a common mechanism. The occurrence of this 
phenomenon in several tissues further implies that  it may be 
a general mechanism for dampening and terminating hor- 
monal signals. 
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